Active Recombinant Human PCSK9 Protein, His-tagged

• Cat.No.: PCSK9-86H
• Product Overview: Recombinant human Proprotein Convertase 9/PCSK9 (Gln31-Gln152 & Ser153-Gln692) with a C-terminal 10-His tag protein was expressed in mouse myeloma cell line.

Specification

• Description: This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia.
• Source: Mammalian cells
• Species: Human
• Tag: His
• Predicted N Terminal: Ser153 (mature form); No results obtained for pro domain, Gln31 inferred from enzymatic pyroglutamate treatment revealing Glu32
• Bio-activity: Measured by its binding ability in a functional ELISA. When Recombinant Human LDL R is coated at 2 µg/mL, Recombinant Human Proprotein Convertase 9/PCSK9 binds with an ED50 of 70-420 ng/mL.
• Molecular Mass: Predicted Molecular Mass: 14 kDa & 59 kDa
  SDS-PAGE: 19 kDa & 66 kDa, reducing conditions
• Endotoxin: <1.0 EU per 1 μg of the protein by the LAL method.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Storage: Avoid repeated freeze-thaw cycles.
  6 months from date of receipt, -20 to -70 centigrade as supplied.
  3 months, -20 to -70 centigrade under sterile conditions after opening.
• Storage Buffer: Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol.

Gene Information

• Gene Name: PCSK9
• Official Symbol: PCSK9 proprotein convertase subtilisin/kexin type 9 [ Homo sapiens (human) ]
• Synonyms: EC 3.4.21; EC 3.4.21.111; FH3; FH3neural apoptosis regulated convertase 1; HCHOLA3; hypercholesterolemia, autosomal dominant 3; LDLCQ1; NARC-1; NARC-1convertase subtilisin/kexin type 9 preproprotein; NARC1EC 3.4.21.-; Neural apoptosis-regulated convertase 1; PC9; PCSK9; Proprotein Convertase 9; proprotein convertase subtilisin/kexin type 9; Subtilisin/kexin-like protease PC9
• Gene ID: 255738
• mRNA Refseq: NM_174936
• Protein Refseq: NP_777596
• MIM: 607786
• UniProt ID: Q8NBP7

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.